DRUG PIPELINE

Regenesance BV is developing a pipeline of compounds that inhibit the complement pathway at various intervention points. Certain compounds have shown efficacy in animal models of acute or chronic nerve degeneration and appear to be well tolerated.

DRUG DISCOVERY

Our MAC-i (MAC inhibitors) development project has produced two classes of polymeric inhibitors. Each class reduces activity of the membrane attack complex (MAC): the terminal lytic component of the complement cascade. One class of compounds has already shown significant activity in an animal model of human neuronal disease and appears to be well tolerated. The MAC-i compounds, as well as others being developed in our NANOPARTICLES project, are intended to provide new and better treatment options for patients suffering from selected peripheral neuropathies and chronic CNS diseases.

DRUG REPOSITIONING

Patients suffering from acute CNS damage (as from a car or motorcycle accident) have few therapeutic options. Recovery and rehabilitation are often slow, expensive and painful for these patients. Regenesance BV has found that a complement inhibitor (RGS 2064) approved for human use can minimize nerve damage in an animal model of traumatic brain injury (TBI). The Company will be seeking partners to help repurpose the compound in Phase I-II clinical trials in Q4 of 2011.